Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The Nomination Committee's proposal regarding the Board of Humana for the 2022 AGM

Ahead of the Annual General Meeting 2022 the Nomination Committee of Humana AB proposes that the Board be composed of six directors elected at the Annual General Meeting, with no alternates, for the period until the next Annual General Meeting. The Nomination Committee proposes re-election of Karita Bekkemellem, Kirsi Komi, Monica Lingegård, Sören Mellstig, Anders Nyberg and Fredrik Strömholm as directors and proposes that Sören Mellstig be re-elected Chairman of the Board.The Nomination Committee prior to the 2022 AGM comprises the following members: Fredrik Strömholm, appointed by Impilo

Invitation to presentation of Bulten’s Q4 report 2021

Bulten’s full year report for the period January – December 2021 will be published on Thursday 10 February 2022 at 13:30 CET.A presentation for analysts, media and investors will be held the same day at 15:30 CET. The report will be presented by President and CEO Anders Nyström and CFO Anna Åkerblad via audiocast. The presentation will be held in English and can be followed live via the link: https://tv.streamfabriken.com/bulten-q4-2021. It will also be possible to take part of the audiocast afterwards at the same address or at www.bulten.com/ir. To participate in the teleconference,

Recipharm secures vaccine manufacturing deal

Global contract development and manufacturing organization (CDMO), Recipharm, has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France. The agreement was announced following the successful quality audit and will see Recipharm aseptically pack single-use vaccines, used to treat a severe infectious disease that affects both young children and infants. The containers will be efficiently filled using Recipharm’s specialist blow-fill-seal (BFS) capabilities, creating products that are quick to distribute and simplifying

EQT Future strengthens its Mission Board with global impact experts

EQT Future is proud to announce the appointment of three high-caliber business executives with strong impact expertise to its Mission Board. The purpose of EQT Future’s Mission Board is to provide external objectivity to the fund’s strategic direction and set the bar high for its commitment to drive positive impact. The Mission Board will be a close sparring partner to EQT Future’s Investment Advisory Team and will challenge and support them throughout the fund’s investment processesThe individuals joining the Mission Board are Ho Ching, recently retired CEO of Temasek; Naina Lal Kidwai,

Climate-smart Viking Glory is also a flagship for sustainability

Waste heat from the vessel’s engines is converted into electricity, while waste cold from liquefied natural gas is used for cooling. Its hull minimizes water resistance, and an intelligent automated control system turns off air conditioning in empty cabins. The new Viking Glory’s innovative solutions make it one of the world’s most climate-smart passenger ships.When Viking Glory is launched in service in March, the environmental impact of Viking Line’s vessels on the Turku–Mariehamn–Stockholm route will be further reduced. For example, Viking Glory has 66 per cent more cargo capacity than

UPM financial statements release 2021: Earnings back to strong pre-pandemic levels, refined completion plan for Uruguay project ready

UPM-Kymmene Corporation        Financial Statements Release 2021        27 January 2022 at 10:00 EET UPM financial statements release 2021:Earnings back to strong pre-pandemic levels, refined completion plan for Uruguay project ready Q4 2021 highlights · Sales increased by 22% to EUR 2,673 million (2,188 million in Q4 2020) · Comparable EBIT increased by 83% to EUR 461 million, 17.2% of sales (252 million, 11.5%) · Operating cash flow was EUR 406 million (347 million) · Net debt increased to EUR 647 million (56 million) and net debt to EBITDA ratio was 0.35 (0.04) ·

Idogen presents the company's technology platform at a scientific congress

Idogen AB (publ) has been invited to present its technology platform for tolerogenic cell therapy at the scientific congress 5th Antigen-Specific Immune Tolerance Summit on 27 January, 2022. This annual meeting involves leading researchers in the field; ranging from American universities to representatives from both large pharmaceutical companies and innovative biotechnology companies.   Idogen develops tolerogenic cell therapies for the treatment of unwanted activation of the immune system. In 2021, the company has taken great strides forward with its most advanced development

Invitation to Readly’s Q4 presentation on 3 February

Readly will publish its interim report for the fourth quarter 2021 on 3 February at 07:30 CET. The report will be presented in an audio cast and tele conference at 09.00 CET the same day.Mats Brandt, interim CEO and Johan Adalberth, CFO, will present the report and answer questions.The presentation will be held in English. To listen to the conference by phone, please call: SE:+46850558351DE: +4969222239165UK: +443333009262US: +16467224956Follow the presentation live on: Link to audio cast  Report and presentation

Cereno Scientific announces milestone has been reached as part of preclinical CS014 program

Cereno Scientific (XSAT: CRNO B) today announced that the progress made in preclinical program CS014 has triggered an undisclosed milestone payment to Emeriti Bio from which CS014 was acquired in 2019. CS014 is currently undergoing a preclinical development program in collaboration with the University of Michigan. Based on this progress a new patent application has been filed.“When we acquired the CS014 program from Emeriti Bio back in 2019 we thought it was a good complement to our CVD portfolio showing exciting innovative properties. As we have continued its development our belief in this

BioStock: CombiGene sails with tailwinds

Gene therapy company CombiGene is speedily progressing in its projects. The exclusive, global licensing agreement for its gene therapy candidate CG01 that was signed with pharmaceutical giant Spark Therapeutics last fall, was followed last week by the news that GMP production of CG01 has been made available for the final preclinical studies that precede the first in-human study. The company has now also signed an agreement with University of Michigan Medical School, regarding the lipodystrophy project CGT2. BioStock spoke to CEO Jan Nilsson to learn more.Read the full interview with Jan

Fuud communicates financial forecast for 2022 and provides operational update

STOCKHOLM, 27 Jan, 2022 08.30 CET Fuud submits a revenue forecast for the year 2022. Fuud's assessment is that sales in 2022 will amount to approximately SEK 170 million organically from current operations. In addition, the company is expected to make a number of acquisitions during 2022. The company's assessment is that it will achieve a positive cash flow and positive EBITDA result during the fourth quarter of 2022. Fuud also communicates operational events that have recently occurred or are imminent.· Forecast organic sales 2022: SEK 170 million (Pro forma Jan-Sep 2021: SEK 50.8

Panoro Energy Announces Receipt of Government Approvals of the Sale of all its Interest in OML 113, offshore Nigeria

Oslo, 27 January 2022 – Panoro Energy ASA (“Panoro” or the “Company”) is pleased to announce that all government approvals have now been received for the sale of the shares of its fully-owned subsidiaries (the “Shares”) that hold 100% of the shares in Pan Petroleum Aje Limited ("Pan Aje") ("the Transaction") to PetroNor E&P Limited (“PetroNor”).  Pan Aje participates in the exploration for and production of hydrocarbons in Nigeria and holds a 6.502% participating interest, with 16.255% cost bearing interest, representing an economic interest of 12.1913% in Oil Mining Lease 113 (“OML 113”),

Beijer Ref Q4-2021

“2021 was a successful year for Bei­jer Ref, despite major disruptions in the supply chain and a number of lockdowns in our markets. With our decentralised business model and our dedicated employees, we have managed to achieve a sales increa­se of 20%. In 2021, we delivered both strong organic growth and acquisi­tion growth, while operating profit increased by 31%. It is particularly gratifying that all product areas show organic growth during the year. Ove­rall, the company had a good end to 2021 and we are entering 2022 with a strong order book”, says Christopher Norbye, CEO Beijer Ref.

Sedana Medical’s Sedaconda ACD recommended by NICE

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedation in intensive care as an alternative to intravenous sedation.Sedaconda ACD is recommended as an option for delivering inhaled sedation in intensive care in England and Wales when volatile anaesthetics are being considered. Cost modelling shows cost savings compared with intravenous sedation of almost £4,000 per adult patient (30-day time horizon for

LINK Mobility and Selligent Marketing Cloud take the next step in the omnichannel experience by integrating the RCS (SMS 2.0) channel into their platform

Oslo, Norway – 27 January 2022 LINK Mobility, a specialist in mobile messaging and CPaaS (Communication Platform as a Service) solutions and services, continues to deploy RCS in France by partnering with Selligent Marketing Cloud, an advanced SaaS omnichannel marketing platform. With this partnership, Selligent becomes one of the first marketing automation platforms in Europe to make the RCS channel, the new generation of multimedia SMS, available to its customers.Referred to as the successor of SMS or SMS 2.0, Rich Communication Services (RCS) refers to a message, available in the Android

2020 Bulkers Ltd. (2020) - Conversion of index-linked charter hire for Bulk Shanghai

Hamilton, Bermuda, January 27, 2022   2020 Bulkers has converted the index-linked charter for Bulk Shanghai into fixed rate charter at US$30,905 per day, gross, for the period from February 1, 2022, until December 31, 2022. In addition, the vessel will still earn a premium related to the fuel cost savings from the scrubbers.   For further queries, please contact:  Magnus Halvorsen, Chief Executive Officer, 2020 Bulkers Management AS  Telephone +47 920 20 111    About 2020 Bulkers Ltd. 2020 Bulkers has eight Newcastlemax dry bulk vessels in operation. All vessels

Foamit Group’s Norwegian subsidiary Glasopor AS supplies foam glass aggregate to new hospital site in Drammen, Norway

Partnera CorporationPress release January 27, 2022 at 9.00 (EET)   Foamit Group’s Norwegian subsidiary Glasopor AS supplies foam glass aggregate to new hospital site in Drammen, Norway The Norwegian subsidiary Glasopor of Foamit Group, which is part of Partnera Corporation, has signed a contract of a large-scale foam glass aggregate delivery for the building of a new hospital in Drammen, Norway. The contract has an order volume of 53,000 m3 foam aggregate. The new hospital in Drammen will have a gross area of 122,000 m2.   · This is a significant order for Glasopor that

REPORT ON THE FOURTH QUARTER 2021

32% SALES GROWTH AND RECORD HIGH BACKLOG FOURTH QUARTER 2021 · Net sales were SEK 5,542 m (4,213); an increase of 32%, of which 2% was organic growth. · Operating profit (EBITDA) was SEK 771 m (701), representing a margin of 13.9% (16.6%). · Operating profit (EBITA) before items affecting comparability was SEK 632 m (536), representing a margin of 11.4% (12.7%). · Operating profit (EBIT) before items affecting comparability was SEK 507 m (466), representing a margin of 9.2% (11.1%). · Operating profit (EBIT) was SEK 470 m (514), representing a margin of 8.5% (12.2%). ·

Interim Report October - December, Q4

Fourth quarter · Net sales increased 62.6 percent to SEK 108.5 (66.7) million · EBIT was SEK 16.2 (-4.0) million · The EBIT margin was 15.0 (-6.0) percent · Profit after tax amounted to SEK 12.7 (-7.0) million · Earnings per share before/after dilution amounted to SEK 0.7 (-0.4) · Cash flow from operating activities amounted to SEK 10.5 (47.2) million. January - December · Net sales increased 7.4 percent to SEK 333.0 (310.1) million · EBIT was SEK 44.3 (28.6) million · The EBIT margin was 13.3 (9.2) percent · Profit after tax amounted to SEK 34.8 (16.3)

NextCell Pharma publishes Interim Report 1 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reportNextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.First quarter (2021-09-01 until 2021-11-30) ● Operating income amounted to TSEK 1 347 (1 148).● Operating result amounted to TSEK -6 472 (-5 473).● Earnings per share* amounted to

Invitation to presentation of BioArctic’s Full Year Report for January - December 2021 on February 3 at 9.30 a.m. CET

Stockholm, Sweden, January 27, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for January – December 2021 on Thursday, February 3, 2022, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on February 3, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Full Year Report for January –  December 2021, followed by a Q&A-session.  To attend, please dial-in at one of the numbers below, from:

PlanetSide 2 Launches New Major Update

EG7 today announces the launch of Expedition: Oshur, the latest major update in PlanetSide 2, the award-winning massively multiplayer online first-person shooter game currently available on PC and PlayStation 4, and one of EG7’s largest own IP:s. The Expedition: Oshur update reveals the lost isles of Oshur, the first water-based continent ever released in the game. Players will discover new tropical, savannah, and coral reef biomes, with 900 combatants waging war by land, air, and sea. Some of the key features of Expedition: Oshur include two new major facilities, water-based warfare,

SAS Annual and Sustainability Report – Fiscal Year  2021

At a Board meeting of SAS AB, the November 2020-October 2021 Annual and Sustainability Report for the SAS Group and its parent company SAS AB was presented and approved.The Annual and Sustainability Report is now available digitally on: https://www.sasgroup.net under "Investor Relations". The Board of Directors proposes to the 2022 AGM that no dividends will be paid to holders of SAS AB’s common shares for fiscal year 2021.Apart from this, the report does not contain any new substantial information which has not already been disclosed in SAS’s year-end report or via separate press

Orexo Q4 2021, incl. Full Year Report

Ready to capitalize on a strong foundation Q4 2021 highlights · Total net revenues of SEK 144.0 m (159.2) · Net earnings of SEK -66.0 m (-49.6) · EBITDA of SEK -48.5 m (1.0) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 133.6 m (143.1), in local currency USD 15.1 m (16.7), US Pharma EBIT of SEK 72.2 m (94.4) · Cash flow from operating activities of SEK -80.6 m (-11.2), cash balance of SEK 504.1 m (505.3) · Earnings per share before and after dilution amounted to -1.92 (-1.45) · Positive outcome announced for the pivotal trial for the lead pharmaceutical

There are no items matching the current filter
There are no more items matching the current filter
Back to top